|
Company Shares of NxStage Medical, Inc. Drops by -3.52% - News Watch International |
 |
|
NxStage Medical, Inc. (NASDAQ:NXTM) has lost 3.52% during the past week and dropped 10.94% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 2.37%. NxStage Medical, Inc. (NASDAQ:NXTM) has underperformed the index by 10.25% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
The company shares have rallied 3.26% from its 1 Year high price. On Apr 27, 2015, the shares registered one year high at $19.63 and the one year low was seen on Sep 16, 2014. The 50-Day Moving Average price is $15.74 and the 200 Day Moving Average price is recorded at $17.31. The company executives own 2.3% of Nxstage Medical, Inc. Company shares. In the past six months, there is a change of -5.2% in the total insider ownership. Institutional Investors own 96.1% of Company shares. During last 3 month period, 2.44% of total institutional ownership has changed in the company shares. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The (President), of Nxstage Medical, Inc., Turk Joseph E Jr had unloaded 2,000 shares at $15.36 per share in a transaction on June 23, 2015. The total value of transaction was $30,720. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Shares of NxStage Medical, Inc. (NASDAQ:NXTM) ended Thursday session in red amid volatile trading. The shares closed down 0.24 points or 1.66% at $14.25 with 357,402 shares getting traded. Post opening the session at $14.54, the shares hit an intraday low of $14.115 and an intraday high of $14.55 and the price vacillated in this range throughout the day. The company has a market cap of $901 million and the number of outstanding shares has been calculated to be 63,238,000 shares. The 52-week high of NxStage Medical, Inc. (NASDAQ:NXTM) is $19.63 and the 52-week low is $11.5. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.
NO COMMENTS
LEAVE A REPLY Cancel reply
|